AstraZeneca vaccine – A corner of the veil rises on its side effects

AstraZeneca vaccine – A corner of the veil rises on its side effects
AstraZeneca vaccine – A corner of the veil rises on its side effects

Several new information has been unveiled around the AstraZeneca vaccine and its side effects. Countries have also decided to set an age limit for administration of the vaccine. Summary of these different points.

Posted today at 15:53

The European Medicines Agency (EMA) first acknowledged on Wednesday that the AstraZeneca vaccine can cause very rare blood problems in some people.


How to explain the serious – and rare – blood problems observed in some people vaccinated against Covid-19 with AstraZeneca? Here are some answers.

The European Medicines Agency (EMA) first acknowledged on Wednesday that the AstraZeneca vaccine can cause very rare blood problems in some people. According to her, this “possible link” justifies the risk being mentioned in the vaccine leaflet.

These undesirable effects are not banal thrombosis (formation of blood clots), as initially reported, but a “very atypical” phenomenon, according to the terms of the French Medicines Agency (ANSM). These are “very rare cases of blood clots combined with low levels of blood platelets,” the EMA explained on Wednesday.

These thromboses, which occurred “within two weeks after vaccination”, affect “veins of the brain (thrombosis of the cerebral venous sinuses) and the abdomen”, according to the EMA. They are sometimes accompanied by bleeding, which may seem paradoxical when it comes to blood clots.

In mid-March, the Paul-Ehrlich Medical Institute (PEI), which advises the German government, was the first to point out “a striking accumulation of a specific form of very rare cerebral venous thrombosis, linked to a deficiency of platelets. blood ”.

What’s the risk?

According to the latest figures from the EMA, on April 4, there were 222 cases of these atypical thromboses out of 34 million injections carried out with AstraZeneca in the European Economic Area (EU, Iceland, Norway, Liechtenstein) and the Kingdom -United. This resulted in 18 deaths.

In Germany, the country where the alert came from, 31 suspected cases of cerebral venous thrombosis (19 of which were accompanied by a fall in blood platelets) were listed at this stage, with 9 deaths, according to the Paul Institute. -Ehrlich. This represents a proportion of one case per 100,000 injected doses (2.8 million).

In the United Kingdom, where we have widely vaccinated with AstraZeneca, there are 79 cases and 19 deaths, out of more than 20 million doses administered, according to a report released on Wednesday by the British drug regulator, the MHRA, alongside the announcements. of the EMA.

Cases have also been reported in France (12, including 4 deaths, out of 1.9 million injections according to the ANSM), in Norway (5 cases, including 3 deaths, out of 120,000 injections) or in the Netherlands.

But as with any drug, knowing the risk is not enough: it must be compared with the benefits provided by the product. This is called the benefit-risk balance.

“Covid-19 carries a risk of hospitalization and death. The combination of blood clots / low platelets that has been reported is very rare, and the overall benefits of the vaccine in preventing Covid-19 outweigh the risks of side effects, ”insisted the EMA on Wednesday , as it has done several times since the first alerts.

Risk factors?

For the moment, most of the cases concern “women under 60 years”, underlined the EMA. But no conclusion can be drawn from this, because it may come from the fact that this vaccine was initially mainly used on young populations.

In addition, the fact that there are mainly women among the reported cases may be linked to the fact that this vaccine has been injected a lot into health professionals, a priority category. However, these professions are very feminized.

In the UK, where the population categories vaccinated with AstraZeneca were wider than elsewhere, cases involve 51 women and 28 men aged 18 to 79.

An age limit?

After a first wave of suspension in mid-March, several countries have decided to no longer administer this vaccine below a certain age: 30 years for the United Kingdom, 55 years for France, Belgium and Canada, 60 years for Germany and the Netherlands, or 65 for Sweden and Finland.

“We don’t have just one vaccine, we have several. This is why reserving AstraZeneca for older people seems to me to make sense, ”commented virologist from Goethe University in Frankfurt, Sandra Ciesek, in Science magazine.

Here again, this reasoning is based on the risk-benefit balance, which varies according to age: the older we get, the more we have a risk of developing a serious form of Covid, and the more it is in our interest to be vaccinated with AstraZeneca, despite the risk of side effects.

Norway and Denmark have made a more drastic choice than just age limits, by stopping the AstraZeneca vaccine altogether for now.

What reasons?

Although we are not sure, several elements support an abnormal and powerful immune response elicited by the vaccine. In a study published online on March 28, but not yet evaluated by other scientists, researchers from Germany and Austria made the connection with another mechanism.

The phenomenon associated with the AstraZeneca vaccine “clinically resembles heparin-induced thrombocytopenia (HIT)”, write these researchers led by Andreas Greinacher (University of Greifswald). HIT is a serious and rare immune reaction triggered in some patients by the anticoagulant drug heparin.

Other French researchers and doctors, united in the collective Du Côté de la Science, put forward an original hypothesis. They believe it is possible that the starting point is “the accidental injection of the vaccine into a vein in the deltoid muscle” (of the shoulder), which would trigger a “discordant immune response”.


Posted today at 15:53

Found an error? Report now.

Get the latest news delivered to your inbox

Follow us on social media networks

PREV Automobile: exports increase by 4.1% at the end of February
NEXT a quarter of French people want to move in 2021